Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ranibizumab Control

Monoclonal antibody · developed by AbbVie

Phase 3 Most advanced trial
ABBV Developer

What is Ranibizumab Control?

Ranibizumab is an antibody fragment that binds vascular endothelial growth factor A and blocks its activity, reducing angiogenesis. It is studied in neovascular age-related macular degeneration, a disease of the eye.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Therapy area
Ophthalmology
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

Conditions studied

Neovascular Age-related Macular Degeneration

More from AbbVie

Follow ABBV, the company behind Ranibizumab Control

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.